Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.09M 5.22M 4.89M 4.47M 8.43M 581M 8.51M 57.67M 22.45M 293M 22.87M 22.37M 970M	P/E 2024	-0.23x	P/E 2025	-0.28x
Enterprise Value	553K 474K 444K 405K 765K 52.68M 772K 5.23M 2.04M 26.58M 2.08M 2.03M 88.03M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	85.18%	Yield 2024 *	-	Yield 2025	-

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
07-29	Processa Pharmaceuticals, Inc. - M&A Call
07-29	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors	CI
07-29	Processa buys Vidya Therapeutics, raises $200 million for drug trials	RE
07-29	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director	CI
07-27	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	CI
07-27	Deals of the day-Mergers and acquisitions	RE
05-07	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026	CI
03-20	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026	CI
03-18	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI

11-05	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025	CI
24-04-25	Top Midday Gainers	MT
24-04-25	HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	MT
23-04-04	Benchmark Adjusts Price Target on Processa Pharmaceuticals to $4 From $9, Keeps Speculative Buy Rating	MT
23-04-03	Oppenheimer Adjusts Processa Pharmaceuticals Price Target to $3 From $5, Maintains Outperform Rating	MT

07-30	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
07-29	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS	AQ
05-07	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
01-12	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference	AQ
01-05	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	AQ

23-08-24	Graco: un compounder di qualità sotto gli occhi di tutti
23-08-22	Graco Inc.: Un compounder de calidad bajo el radar
23-08-22	Graco : un compounder de qualité sous les radars

Processa Pharmaceuticals, Inc. Stock Other OTC

Stocks

Biotechnology & Medical Research

Valuation: Processa Pharmaceuticals, Inc.

Latest news : Processa Pharmaceuticals, Inc.

Last Transcript: Processa Pharmaceuticals, Inc.

Analysts' recommendations: Processa Pharmaceuticals, Inc.

Press Releases: Processa Pharmaceuticals, Inc.

News in other languages: Processa Pharmaceuticals, Inc.

Managers and Directors: Processa Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
George Ng CEO	Chief Executive Officer	52	2023-08-07
Patrick Lin IRC	Investor Relations Contact	60	2011-03-28
Wendy Guy ADM	Chief Administrative Officer	61	2017-10-03

Director	Title	Age	Since
David Young CHM	Chairman	73	2011-03-28
Justin Yorke CHM	Chairman	60	2022-08-15
Geraldine Pannu BRD	Director/Board Member	56	2020-02-12

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROCESSA PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	6.06M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	69.06B
ARGENX SE	+1.74%	+1.06%	+49.02%	+87.38%	63.06B
BIONTECH SE	+1.09%	+22.96%	+8.55%	-3.03%	28.34B
INSMED INCORPORATED	-0.07%	-3.56%	-3.45%	+467.26%	27.07B
WUXI BIOLOGICS (CAYMAN) INC.	+7.41%	+7.45%	+56.85%	+17.70%	25.45B
GENMAB A/S	+3.98%	+4.37%	+39.47%	-14.65%	19.69B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	19.19B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.10%	-3.50%	+11.43%	+519.16%	15.95B
EXELIXIS, INC.	+3.98%	+6.78%	+49.66%	+157.94%	13.52B
Average	+2.26%	+4.20%	+60.22%	+195.08%	31.26B
Weighted average by Cap.	+2.52%	+3.06%	+55.82%	+155.97%

	2024	2025
Net sales	-	-
Net income	-11.85M -10.15M -9.51M -8.69M -16.4M -1.13B -16.56M -112M -43.69M -570M -44.49M -43.53M -1.89B	-13.56M -11.62M -10.89M -9.95M -18.77M -1.29B -18.96M -128M -50.01M -652M -50.93M -49.82M -2.16B
Net Debt	-1.12M -958K -898K -820K -1.55M -107M -1.56M -10.59M -4.12M -53.77M -4.2M -4.11M -178M	-5.54M -4.74M -4.45M -4.06M -7.66M -528M -7.74M -52.44M -20.41M -266M -20.79M -20.34M -882M